Top

Published in:

01-10-2017 | Editorial

Return-to-work outcomes in cancer survivors

Author: Richard Crevenna

Published in: Supportive Care in Cancer | Issue 10/2017

Excerpt

Return to work seems to be a relevant and important issue for cancer patients [1‐3]. About 60% of patients are able to work following a cancer diagnosis, and multidisciplinary programs have been shown to help cancer survivors to return to work [1‐3]. …

Ullrich A, Rath HM, Otto U, Kerschgens C, Raida M, Hagen-Aukamp C, Bergelt C. Outcomes across the return-to-work process in prostate cancer survivors attending a rehabilitation measure—results from a prospective study. Support Care Cancer 2017 XXX

de Boer AG, Taskila T, Tamminga SJ et al (2011) Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev 16:CD007569

Hellbom M, Bergelt C, Bergenmar M et al (2011) Cancer rehabilitation: a Nordic and European perspective. Acta Oncol 50:179–186CrossRefPubMed

Wasiak R, Young AE, Roessler RT et al (2007) Measuring return to work. J Occup Rehabil 17:766–781CrossRefPubMed

Bilodeau K, Tremblay D, Durand MJ. Exploration of return-to-work interventions for breast cancer patients: a scoping review. Support Care Cancer 2017 Jun;25(6):1993–2007. doi: 10.1007/s00520-016-3526-2. Epub 2017 Jan 4

Crevenna R. Crevenna R. Cancer Rehabilitation and palliative care—two important parts of comprehensive cancer care. Support Care Cancer 2015 Dec;23(12):3407–3408. doi: 10.1007/s00520-015-2977-1. Epub 2015 Oct 6

Keilani M, Hasenoehrl T, Neubauer M, Crevenna R. Resistance exercise and secondary lymphedema in breast cancer survivors—a systematic review. Support Care Cancer 2016 Apr;24(4):1907–1916. doi: 10.1007/s00520-015-3068-z. Epub 2015 Dec 30

Neubauer M, Schoberwalter D, Cenik F, Keilani M, Crevenna R. Lymphedema and employability—review and results of a survey of Austrian experts. Wien Klin Wochenschr 2017 Mar;129(5–6):186–191. doi: 10.1007/s00508-017-1167-1. Epub 2017 Jan 26

Title: Return-to-work outcomes in cancer survivors
Author: Richard Crevenna
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 10/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3835-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2017

Reliability and validity of the Pittsburgh Sleep Quality Index in breast cancer patients

Low-level laser and antimicrobial photodynamic therapy on experimental periodontitis in rats submitted to chemotherapy by 5-fluorouracil

Barriers to information provision regarding breast cancer and its treatment

Reply to: MASCC/ESMO consensus recommendations for the management of nausea and vomiting in advanced cancer

Patient-reported outcomes in cancer survivors: a population-wide cross-sectional study

High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain

Keynote webinar | Spotlight on antibody–drug conjugates in cancer